Our group identified a mechanism for CaMKII activation by oxidation of paired Met residues (281/282) in the CaMKII regulatory domain, and found that angiotensin II (Ang II) infusion leads to myocardial Met 281/282 oxidation, locking oxidized CaMKII (ox- CaMKII) into a persistently active configuration. We recently found that expression of ox- CaMKII is increased in atria from AF patients compared to controls, leading us to develop and validate a mouse model of Ang II infusion and enhanced AF susceptibility to test the potential role of ROS and ox-CaMKII in AF. We found that Ang II-infused mice with pacing-induced paroxysmal AF and mice with gene targeted myocardial expression of angiotensin converting enzyme and spontaneous AF, resembled AF patients by showing increased atrial ox-CaMKII. Our proposal will test the novel hypothesis that ox-CaMKII is a critical, but previously unrecognized, signaling mechanism for driving proarrhythmic events that favor AF using the following specific aims. 1. Determine if increased ox-CaMKII is necessary for proarrhythmic effects of Ang II on AF. Experiments planned in the aim will map the hypothesized 'upstream'elements of our proposed pathway and measure the contribution of NADPH oxidase, MsrA activity and CaMKII Met oxidation on ox-CaMKII levels and AF induction. 2. Determine if ox-CaMKII favors AF initiation. Studies in this aim will test a molecular and cellular mechanism 'downstream'to ox-CaMKII that we hypothesize explains increased AF induction by ox-CaMKII through increased SR Ca2+ uptake and release, inward INCX and delayed afterdepolarizations (DADs). 3. Determine if ox-CaMKII contributes to AF substrate through atrial enlargement and fibrosis. These experiments will determine if excessive ox-CaMKII contributes to proarrhythmic atrial remodeling by promoting expression of matrix metalloproteinase (favoring atrial enlargement), transforming growth factor b1 and atrial myocyte death (inducing reactive and reparative atrial fibrosis).

Public Health Relevance

Atrial fibrillation (AF) is a major public health problem without adequate treatments. AF causes suffering and death and costs the U.S. healthcare system $26 billion annually. Thus, studies that provide improved understanding of the mechanisms responsible for AF are highly significant. AF initiation in atrial myocytes and proarrhythmic tissu remodeling that supports AF maintenance are both regarded as important targets for clinical management of AF. However, currently available therapies mostly target individual processes, potentially explaining why a high percentage of patients are not adequately treated. The ox-CaMKII pathway, which we discovered and will study in this proposal, may be a unifying mechanism for multiple events that favor AF initiation and maintenance, suggesting that CaMKII inhibition or methionine-targeted antioxidants could be useful new AF therapies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL113001-03
Application #
8628170
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Krull, Holly
Project Start
2012-04-01
Project End
2017-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
3
Fiscal Year
2014
Total Cost
$369,950
Indirect Cost
$124,950
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Luczak, Elizabeth D; Anderson, Mark E (2014) CaMKII oxidative activation and the pathogenesis of cardiac disease. J Mol Cell Cardiol 73:112-6
Hund, Thomas J; Snyder, Jedidiah S; Wu, Xiangqiong et al. (2014) ?(IV)-Spectrin regulates TREK-1 membrane targeting in the heart. Cardiovasc Res 102:166-75
Zhu, Zhiyong; Sierra, Ana; Burnett, Colin M-L et al. (2014) Sarcolemmal ATP-sensitive potassium channels modulate skeletal muscle function under low-intensity workloads. J Gen Physiol 143:119-34
Ho, Hsiang-Ting; Liu, Bin; Snyder, Jedidiah S et al. (2014) Ryanodine receptor phosphorylation by oxidized CaMKII contributes to the cardiotoxic effects of cardiac glycosides. Cardiovasc Res 101:165-74
Chakraborty, Asima; Pasek, Daniel A; Huang, Tai-Qin et al. (2014) Inhibition of CaMKII does not attenuate cardiac hypertrophy in mice with dysfunctional ryanodine receptor. PLoS One 9:e104338
Wolf, Roseanne M; Glynn, Patric; Hashemi, Seyed et al. (2013) Atrial fibrillation and sinus node dysfunction in human ankyrin-B syndrome: a computational analysis. Am J Physiol Heart Circ Physiol 304:H1253-66
Ather, Sameer; Wang, Wei; Wang, Qiongling et al. (2013) Inhibition of CaMKII phosphorylation of RyR2 prevents inducible ventricular arrhythmias in mice with Duchenne muscular dystrophy. Heart Rhythm 10:592-9
Sierra, Ana; Zhu, Zhiyong; Sapay, Nicolas et al. (2013) Regulation of cardiac ATP-sensitive potassium channel surface expression by calcium/calmodulin-dependent protein kinase II. J Biol Chem 288:1568-81
DeGrande, Sean T; Little, Sean C; Nixon, Derek J et al. (2013) Molecular mechanisms underlying cardiac protein phosphatase 2A regulation in heart. J Biol Chem 288:1032-46
Gao, Zhan; Rasmussen, Tyler P; Li, Yue et al. (2013) Genetic inhibition of Na+-Ca2+ exchanger current disables fight or flight sinoatrial node activity without affecting resting heart rate. Circ Res 112:309-17

Showing the most recent 10 out of 19 publications